Recent Publications




Additional Publications

Recent Publications:

1.        Zou W. Mechanistic insights into cancer immunity and immunotherapy. Cell Mol Immunol 2018;15:419-420.

2.         Yan TT, Ren LL, Shen CQ, et al. miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer.                 Cancer Res 2018;78:1751-1765.

3.         Wu YM, Cieslik M, Lonigro RJ, et al. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of                         Advanced Prostate Cancer. Cell 2018;173:1770-1782 e14.

4.         Wang W, Zou W, Liu JR. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and                     biological basis of immunotherapy. Gynecol Oncol 2018;151:1-3.

5.         Lin H, Wei S, Hurt EM, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-                        mediated tumor regression. J Clin Invest 2018;128:805-815.

6.         Li W, Tanikawa T, Kryczek I, et al. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor                 Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metab 2018;28:87-103 e6.

7.         Hu X, Majchrzak K, Liu X, et al. In Vitro Priming of Adoptively Transferred T Cells with a RORgamma Agonist                 Confers Durable Memory and Stemness In Vivo. Cancer Res 2018;78:3888-3898.

8.         Crespo J, Wu K, Li W, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J                 Immunol 2018;201:814-820.

9.         Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for                 effective therapy. Nat Med 2018;24:541-550.

10.       Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by                         Modulating Autophagy. Cell 2017;170:548-563 e16.

11.       Xia H, Wang W, Crespo J, et al. Suppression of FIP200 and autophagy by tumor-derived lactate promotes                     naive T cell apoptosis and affects tumor immunity. Sci Immunol 2017;2.

12.       Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer             immunotherapy. Nat Rev Immunol 2017;17:559-572.

13.       Maj T, Wang W, Crespo J, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity                 and PD-L1-blockade resistance in tumor. Nat Immunol 2017;18:1332-1341.

14.       Li J, Xi Y, Li W, et al. TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere             formation. Oncogene 2017;36:2991-3001.

15.       Kryczek I, Frankel T, Zou W. Regulatory T Cell Biology and Its Application in Cancer. Cancer Immunotherapy                 Principles and Practice. L. Butterfiild et.al ed. 2017;First Edition:515-532.

16.       Guo L, Zhang P, Chen Z, et al. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-                to-NASH progression. J Clin Invest 2017.

17.       Frankel T, Lanfranca MP, Zou W. The Role of Tumor Microenvironment in Cancer Immunotherapy. Adv Exp                 Med Biol 2017;1036:51-64.

18.       Fang M, Li Y, Huang K, et al. IL-33 promotes colon cancer cell stemness via JNK activation and macrophage                 recruitment. Cancer Res 2017.

19.       Crespo J, Vatan L, Maj T, et al. Phenotype and tissue distribution of CD28H(+) immune cell subsets.                             Oncoimmunology 2017;6:e1362529.

20.       Bitler BG, Wu S, Park PH, et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol                 2017;19:962-973.